xtandi
astellas pharma europe b.v. - enzalutamide - prostatiset kasvaimet - endokriinihoito - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
profamid 250 mg tabletti
orion corporation - flutamide - tabletti - 250 mg - flutamidi
casodex 50 mg tabletti, kalvopäällysteinen
laboratoires juvise pharmaceuticals - bicalutamide - tabletti, kalvopäällysteinen - 50 mg - bikalutamidi
casodex 150 mg tabletti, kalvopäällysteinen
laboratoires juvise pharmaceuticals - bicalutamide - tabletti, kalvopäällysteinen - 150 mg - bikalutamidi
bicavan 50 mg tabletti, kalvopäällysteinen
avansor pharma oy - bicalutamide - tabletti, kalvopäällysteinen - 50 mg - bikalutamidi
bicavan 150 mg tabletti, kalvopäällysteinen
avansor pharma oy - bicalutamide - tabletti, kalvopäällysteinen - 150 mg - bikalutamidi
bicalutamid orion 50 mg tabletti, kalvopäällysteinen
orion corporation - bicalutamide - tabletti, kalvopäällysteinen - 50 mg - bikalutamidi
bicalutamid orion 150 mg tabletti, kalvopäällysteinen
orion corporation - bicalutamide - tabletti, kalvopäällysteinen - 150 mg - bikalutamidi
bicalutamide bluefish 50 mg tabletti, kalvopäällysteinen
bluefish pharmaceuticals ab bluefish pharmaceuticals ab - bicalutamidum - tabletti, kalvopäällysteinen - 50 mg - bikalutamidi
bicalutamide bluefish 150 mg tabletti, kalvopäällysteinen
bluefish pharmaceuticals ab bluefish pharmaceuticals ab - bicalutamidum - tabletti, kalvopäällysteinen - 150 mg - bikalutamidi